Aug 20, 2021
Bispecific antibody of AstraZeneca derived from COM902 to enter clinical development, Health News, ET HealthWorld
Bispecific antibody of AstraZeneca derived from COM902 to enter clinical development, Health News, ET HealthWorld
Holon, Israel : Compugen Ltd, a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen’s high affinity anti-TIGIT antibody, will advance into clinical development. AstraZeneca plans to initiate a phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in…
View On WordPress